Delivery of therapeutic proteins.
The safety and efficacy of protein therapeutics are limited by three interrelated pharmaceutical issues, in vitro and in vivo instability, immunogenicity and shorter half-lives. Novel drug modifications for overcoming these issues are under investigation and include covalent attachment of poly(ethylene glycol) (PEG), polysialic acid, or glycolic acid, as well as developing new formulations containing nanoparticulate or colloidal systems (e.g., liposomes, polymeric microspheres, polymeric nanoparticles). Such strategies have the potential to develop as next generation protein therapeutics. This review includes a general discussion on these delivery approaches.
Pisal
Dipak S
DS
Department of Pharmaceutical Sciences, 521 Hochstetter Hall, University at Buffalo, The State University of New York, Amherst, New York 14260, USA.
Kosloski
Matthew P
MP
Balu-Iyer
Sathy V
SV
D002626:Chemistry, Pharmaceutical; D006207:Half-Life; D006801:Humans; D008081:Liposomes / Q000493:pharmacokinetics; D008863:Microspheres; D053758:Nanoparticles / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry; D011108:Polymers / Q000737:chemistry; D011506:Proteins / Q000008:administration & dosage*; D012794:Sialic Acids
D008081:Liposomes; D011108:Polymers; D011506:Proteins; D012794:Sialic Acids; C021319:polysialic acid; D011092:Polyethylene Glycols